On Friday, Jefferies adjusted its stock price target for Cue Biopharma (NASDAQ:CUE), bringing it down to $4.00 from the previous $6.00, while maintaining a Buy rating on the company's stock. This move comes despite the stock's significant ~230% rise following a recent $12 million capital raise by the biopharmaceutical company.
The analyst at Jefferies noted that although Cue Biopharma's stock has experienced a sharp increase, there is still a substantial cash overhang of $32 million. This financial burden could potentially restrict the company's ability to further advance its CUE-100 series programs, which are central to its research and development efforts.
The firm expressed a positive outlook on the possibility of Cue Biopharma forming a partnership related to its CUE-501 product with a pharmaceutical company. Such a partnership is anticipated to be the next significant event for the stock. It would not only endorse Cue Biopharma's viral epitope strategy and platform but also provide the necessary funding to continue exploring the promising results observed in its oncology programs.
The revision of the price target to $4.00 from the earlier $6.00 reflects the current assessment of the company's financial position and its prospects, particularly in relation to the ongoing development of its oncology programs. The endorsement of a Buy rating indicates that, despite the price target adjustment, Jefferies continues to view Cue Biopharma's stock favorably.
In other recent news, Cue Biopharma has been making significant strides. The company increased its authorized capital, expanding from 110 million to 210 million shares, potentially paving the way for future corporate actions. Cue Biopharma also amended its loan agreement with Silicon Valley Bank, eliminating a fixed cash reserve requirement, which could provide increased financial flexibility.
In further developments, Cue Biopharma initiated a public offering of its common stock and purchase warrants, managed by Oppenheimer & Co. and Newbridge Securities Corporation. The company also welcomed Lucinda Warren, a former Johnson & Johnson executive, as its new chief business officer. This appointment followed the resignation of board member Michael J. Fox, a change that was not due to disagreements with the company.
Adding to these changes, Cue Biopharma has prioritized its autoimmune programs, leading to a 25% workforce reduction. In response, Stifel reduced its price target for the company from $8.00 to $4.00, while Piper Sandler maintained its Overweight rating with a steady price target of $3.00.
Lastly, the company has been actively reducing its debt, which stands at $6.2 million, and ended the second quarter of 2024 with $30 million in cash. These funds are expected to support operations until the second quarter of 2025. These are the recent developments shaping Cue Biopharma's strategic and financial direction.
InvestingPro Insights
Recent InvestingPro data provides additional context to Jefferies' analysis of Cue Biopharma (NASDAQ:CUE). The company's market capitalization stands at $90.31 million, reflecting its current valuation in light of recent developments. Notably, CUE's revenue growth has been impressive, with a 363.67% increase over the last twelve months as of Q2 2024, and a 92.33% quarterly growth in Q2 2024. This robust revenue expansion aligns with the potential that Jefferies sees in the company's CUE-100 series programs.
However, InvestingPro Tips highlight some challenges. The company is "quickly burning through cash" and is "not profitable over the last twelve months," which corroborates Jefferies' concern about the $32 million cash overhang. This financial pressure underscores the importance of the potential partnership for CUE-501 that Jefferies mentioned.
On a positive note, an InvestingPro Tip indicates that CUE "holds more cash than debt on its balance sheet," which could provide some financial flexibility as the company navigates its development phase. Additionally, the stock has shown a "strong return over the last three months," with InvestingPro data revealing a 152.57% price total return over that period, reflecting the significant rise noted in the article.
For investors seeking a more comprehensive analysis, InvestingPro offers 11 additional tips for Cue Biopharma, providing a deeper understanding of the company's financial health and market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.